[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.4062/biomolther.2022.007

Metabolic Bone Diseases and New Drug Developments

Natesan, Vijayakumar (Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University)
Kim, Sung-Jin (Department of Pharmacology and Toxicology, Metabolic Diseases Research Laboratory, School of Dentistry, Kyung Hee University)

Publication Information

Biomolecules & Therapeutics / v.30, no.4, 2022 , pp. 309-319 More about this Journal

Abstract

Metabolic bone diseases are serious health issues worldwide, since several million individuals over the age of 50 are at risk of bone damage and should be worried about their bone health. One in every two women and one in every four men will break a bone during their lifetime due to a metabolic bone disease. Early detection, raising bone health awareness, and maintaining a balanced healthy diet may reduce the risk of skeletal fractures caused by metabolic bone diseases. This review compiles information on the most common metabolic bone diseases (osteoporosis, primary hyperparathyroidism, osteomalacia, and fluorosis disease) seen in the global population, including their symptoms, mechanisms, and causes, as well as discussing their prevention and the development of new drugs for treatment. A large amount of research literature suggests that balanced nutrition and balanced periodic supplementation of calcium, phosphate, and vitamin D can improve re-absorption and the regrowth of bones, and inhibit the formation of skeletal fractures, except in the case of hereditary bone diseases. Meanwhile, new and improved drug formulations, such as raloxifene, teriparatide, sclerostin, denosumab, and abaloparatide, have been successfully developed and administered as treatments for metabolic bone diseases, while others (romososumab and odanacatib) are in various stages of clinical trials.

Keywords

Metabolic bone diseases; Osteoporosis; Osteomalacia; New drugs; Odanacatib;

Citations & Related Records

Times Cited By KSCI : 2 (Citation Analysis)

Reference
Cited By KSCI

1	Curtis, E. M., van der Velde, R., Moon, R. J., van den Bergh, J. P., Geusens, P., de Vries, F., van Staa, T. P., Cooper, C. and Harvey, N. C. (2016) Epidemiology of fractures in the United Kingdom 1988-2012: variation with age, sex, geography, ethnicity, and socioeconomic status. Bone 87, 19-26. DOI
2	Drake, M. T., Clarke, B. L. and Lewiecki, E. M. (2015) The pathophysiology and treatment of osteoporosis. Clin. Ther. 37, 1837-1850. DOI
3	Morgan, B., Mant, M., de la Cova, C. and Brickley, M. B. (2020) Osteoporosis, osteomalacia, and hip fracture: a case study from the Terry collection. Int. J. Paleopathol. 30, 17-21. DOI
4	Natesan, V. and Kim, S. J. (2021a) Diabetic nephropathy-a review of risk factors, progression, mechanism, and dietary management. Biomol. Ther. (Seoul) 29, 365-372. DOI
5	Uday, S. and Hogler, W. (2017) Nutritional rickets and osteomalacia in the twenty-first century: revised concepts, public health, and prevention strategies. Curr. Osteoporos. Rep. 15, 293-302. DOI
6	Albahri, A. S., Alwan, J. K., Taha, Z. K., Ismail, S. F., Hamid, R. A., Zaidan, A. A., Albahri, O. S., Zaidan, B. B., Alamoodi, A. H. and Alsalem, M. A. (2021) IoT-based telemedicine for disease prevention and health promotion: state-of-the-art. J. Netw. Comput. Appl. 173, 102873. DOI
7	Abrahamsen, B., Pazianas, M., Eiken, P., Russell, R. G. and Eastell, R. (2012) Esophageal and gastric cancer incidence and mortality in alendronate users. J. Bone Miner. Res. 27, 679-686. DOI
8	Ackerman, K. E. and Misra, M. (2011) Bone health and the female athlete triad in adolescent athletes. Phys. Sportsmed. 39, 131-141. DOI
9	Al-Azem, H. and Khan, A. A. (2012) Hypoparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 26, 517-522. DOI
10	Swanson, W. B., Zhang, Z., Xiu, K., Gong, T., Eberle, M., Wang, Z. and Ma, P. X. (2020) Scaffolds with controlled release of pro-mineralization exosomes to promote craniofacial bone healing without cell transplantation. Acta Biomater. 118, 215-232. DOI
11	Kim, M. E., Seon, J. K., Kang, J. Y., Yoon, T. R., Lee, J. S. and Kim, H. K. (2021) Bone-forming peptide-4 induces osteogenic differentiation and VEGF expression on multipotent bone marrow stromal cells. Front. Bioeng. Biotechnol. 9, 734483. DOI
12	Dubey, A. K., Handu, S. S., Dubey, S., Sharma, P., Sharma, K. K. and Ahmed, Q. M. (2011) Belimumab: first targeted biological treatment for systemic lupus erythematosus. J. Pharmacol. Pharmacother. 2, 317-319. DOI
13	Fabre, S., Funck-Brentano, T. and Cohen-Solal, M. (2020) Anti-sclerostin antibodies in osteoporosis and other bone diseases. J. Clin. Med. 9, 3439. DOI
14	Kaveh, S., Hosseinifard, H., Ghadimi, N., Vojdanian, M. and Aryankhesal, A. (2020) Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin. Rheumatol. 39, 3261-3276. DOI
15	Kim, M. K., Yun, K. J., Kim, M. H., Lim, D. J., Kwon, H. S., Song, K. H., Kang, M. I. and Baek, K. H. (2015) The effects of thyrotropinsuppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone 71, 101-105. DOI
16	Tuli, G., Buganza, R., Tessaris, D., Einaudi, S., Matarazzo, P. and de Sanctis, L. (2020) Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism. Endocrine 67, 457-465. DOI
17	Tay, D., Cremers, S. and Bilezikian, J. P. (2018) Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. Br. J. Clin. Pharmacol. 84, 252-267. DOI
18	Vijayakumar, N. and Subramanian, P. (2010a) Neuroprotective effect of Semecarpus anacardium against hyperammonemia in rats. J. Pharm. Res. 3, 1564-8.
19	Knechtle, B., Jastrzebski, Z., Hill, L. and Nikolaidis, P. T. (2021) Vitamin D and stress fractures in sport: preventive and therapeutic measures-a narrative review. Medicina 57, 223. DOI
20	Komoroski, M., Azad, N. and Camacho, P. (2014) Disorders of bone and bone mineral metabolism. Handb. Clin. Neurol. 120, 865-887. DOI
21	Nilsson, I. L. (2019) Primary hyperparathyroidism: should surgery be performed on all patients? Current evidence and residual uncertainties. J. Intern. Med. 285, 149-164. DOI
22	Konda, P. Y., Poondla, V., Jaiswal, K. K., Dasari, S., Uyyala, R., Surtineni, V. P. and Natesan, V. (2020) Pathophysiology of high fat diet induced obesity: impact of probiotic banana juice on obesity associated complications and hepatosteatosis. Sci. Rep. 10, 16894. DOI
23	Laroche, M., Couture, G., Ruyssen-Witrand, A., Constantin, A. and Degboe, Y. (2020) Effect of risedronate on bone loss at discontinuation of denosumab. Bone Rep. 13, 100290. DOI
24	Natesan, V. and Kim, S. J. (2021b) Lipid metabolism, disorders and therapeutic drugs - review. Biomol. Ther. (Seoul) 29, 596-604. DOI
25	Ott, S. M. and Elder, G. J. (2021) Osteoporosis associated with chronic kidney disease. In Marcus and Feldman's Osteoporosis, pp. 1325-1380. Academic Press.
26	Pelechas, E., Voulgari, P. V. and Drosos, A. A. (2019) Golimumab for rheumatoid arthritis. J. Clin. Med. 8, 387. DOI
27	Peraza-Delgado, A., Sanchez-Gomez, M. B., Gomez-Salgado, J., Romero-Martin, M., Novo-Munoz, M. and Duarte-Climents, G. (2020) Non-pharmacological interventions towards preventing the triad osteoporosis-falls risk-hip fracture, in population older than 65. scoping review. J. Clin. Med. 9, 2329. DOI
28	Pludowski, P., Holick, M. F., Grant, W. B., Konstantynowicz, J., Mascarenhas, M. R., Haq, A., Povoroznyuk, V., Balatska, N., Barbosa, A. P., Karonova, T., Rudenka, E., Misiorowski, W., Zakharova, I., Rudenka, A., Lukaszkiewicz, J., Marcinowska-Suchowierska, E., Laszcz, N., Abramowicz, P., Bhattoa, H. P. and Wimalawansa, S. J. (2018) Vitamin D supplementation guidelines. J. Steroid Biochem. Mol. Biol. 175, 125-135. DOI
29	Leib, E. S., Saag, K. G., Adachi, J. D., Geusens, P. P., Binkley, N., McCloskey, E. V. and Hans, D. B.; FRAX(®) Position Development Conference Members (2011) Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). J. Clin. Densitom. 14, 212-219. DOI
30	McDonald, J., Wooderchak-Donahue, W., VanSant Webb, C., White-head, K., Stevenson, D. A. and Bayrak-Toydemir, P. (2015) Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front. Genet. 6, 1. DOI
31	Petrone, P., Fabio, M., Guarino, B., Giustino, S. and Gombos, F. (2013) Ancient and recent evidence of endemic fluorosis in the Naples area. J. Geochem. Explor. 131, 14-27. DOI
32	Levine, M. A. (2012) Assessing bone health in children and adolescents. Indian J. Endocrinol. Metab. 16, S205-S212. DOI
33	Lim, S. Y. and Bolster, M. B. (2017) Profile of romosozumab and its potential in the management of osteoporosis. Drug Des. Devel. Ther. 11, 1221-1231. DOI
34	Lombardi, G., Ziemann, E., Banfi, G. and Corbetta, S. (2020) Physical activity-dependent regulation of parathyroid hormone and calciumphosphorous metabolism. Int. J. Mol. Sci. 21, 5388. DOI
35	Polyzos, S. A., Cundy, T. and Mantzoros, C. S. (2018) Juvenile Paget disease. Metab. Clin. Exp. 80, 15-26. DOI
36	Provinciali, N., Suen, C., Dunn, B. K. and DeCensi, A. (2016) Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women. Expert Rev. Clin. Pharmacol. 9, 1263-1272. DOI
37	Ramakrishnan, A. and Vijayakumar, N. (2017) Urea cycle pathway targeted therapeutic action of naringin against ammonium chloride induced hyperammonemic rats. Biomed. Pharmacother. 94, 1028-1037. DOI
38	Ramya, A., Vijayakumar, N. and Renuka, M. (2015) Antiarthritic effect of aqueous extract of lawsonia inermis. L-an in vitro study. Int. J. Modn. Res. Revs. 3, 744-747.
39	Arumugam, R., Natesan, V. and Mani, R. (2016) Effect of naringin on ammonium chloride-induced hyperammonemic rats: a dose-dependent study. J. Acute Med. 6, 55-60. DOI
40	Anderson, H. C., Harmey, D., Camacho, N. P., Garimella, R., Sipe, J. B., Tague, S., Bi, X., Johnson, K., Terkeltaub, R. and Millan, J. L. (2005) Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am. J. Pathol. 166, 1711-1720. DOI
41	Azizieh, F. Y. (2015) Incidence of hip fracture in Kuwait: a national registry-based study. Arch. Osteoporos. 10, 40. DOI
42	Barbosa, J. S., Braga, S. S. and Almeida Paz, F. A. (2020) Empowering the medicinal applications of bisphosphonates by unveiling their synthesis details. Molecules 25, 2821. DOI
43	Berg, S. H., Balogh, E. A., Ghamrawi, R. I. and Feldman, S. R. (2021) A review of secukinumab in psoriasis treatment. Immunotherapy 13, 201-216. DOI
44	Bergwitz, C. and Juppner, H. (2010) Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu. Rev. Med. 61, 91-104. DOI
45	Blau, J. E. and Simonds, W. F. (2021) Familial hyperparathyroidism. Front. Endocrinol. 12, 623667. DOI
46	Bonakdarpour, A. (2009) Systematic approach to metabolic diseases of bone. In Diagnostic Imaging of Musculoskeletal Diseases, pp. 15-59. Springer.
47	Marsh, D., Akesson, K., Beaton, D. E., Bogoch, E. R., Boonen, S., Brandi, M. L., McLellan, A. R., Mitchell, P. J., Sale, J. E. and Wahl, D. A. (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos. Int. 22, 2051-2065. DOI
48	Carbone, L. D., Gonzalez, B., Miskevics, S., Ray, C., Etingen, B., Guihan, M., Craven, B. C., George, V. and Weaver, F. M. (2020) Association of bisphosphonate therapy with incident of lower extremity fractures in persons with spinal cord injuries or disorders. Arch. Phys. Med. Rehabil. 101, 633-641. DOI
49	Lopes, D., Martins-Cruz, C., Oliveira, M. B. and Mano, J. F. (2018) Bone physiology as inspiration for tissue regenerative therapies. Biomaterials 185, 240-275. DOI
50	Lu, J., Wang, M., Wang, Z., Fu, Z., Lu, A. and Zhang, G. (2018) Advances in the discovery of cathepsin K inhibitors on bone resorption. J. Enzyme Inhib. Med. Chem. 33, 890-904. DOI
51	McKeage, K. and Perry, C. M. (2002) Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62, 209-243. DOI
52	Minich, D. M. (2019) A review of the science of colorful, plant-based food and practical strategies for "eating the rainbow". J. Nutr. Metab. 2019, 2125070. DOI
53	Moen, M. D. and Keam, S. J. (2011) Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 28, 63-82. DOI
54	Sahu, P., Kisku, G., Singh, P., Kumar, V., Kumar, P. and Shukla, N. (2018) Multivariate statistical interpretation on seasonal variations of fluoride-contaminated groundwater quality of Lalganj Tehsil, Raebareli District (UP), India. Environ. Earth Sci. 77, 484. DOI
55	Cavalier, E., Bergmann, P., Bruyere, O., Delanaye, P., Durnez, A., Devogelaer, J. P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J. M., Toukap, A. N., Reginster, J. Y., Rousseau, A. F., Rozenberg, S., Scheen, A. J. and Body, J. J. (2016) The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos. Int. 27, 2181-2195. DOI
56	Chinoy, A., Mughal, M. Z. and Padidela, R. (2019) Metabolic bone disease of prematurity: causes, recognition, prevention, treatment and long-term consequences. Arch. Dis. Child. Fetal Neonatal Ed. 104, F560-F566. DOI
57	Rasool, A., Farooqi, A., Xiao, T., Ali, W., Noor, S., Abiola, O., Ali, S. and Nasim, W. (2018) A review of global outlook on fluoride contamination in groundwater with prominence on the Pakistan current situation. Environ. Geochem. Health 40, 1265-1281. DOI
58	Reyes, C., Hitz, M., Prieto-Alhambra, D. and Abrahamsen, B. (2016) Risks and benefits of bisphosphonate therapies. J. Cell. Biochem. 117, 20-28. DOI
59	Rivadeneira, F. and Makitie, O. (2016) Osteoporosis and bone mass disorders: from gene pathways to treatments. Trends Endocrinol. Metab. 27, 262-281. DOI
60	Sanghi, D., Saini, P., Mishra, P. and Sharma, M. (2021) Outbreaks in India: impact on socio-economy and health. J. Commun. Dis. 53, 35-44.
61	Scollon, S., Anglin, A. K., Thomas, M., Turner, J. T. and Wolfe Schneider, K. (2017) A comprehensive review of pediatric tumors and associated cancer predisposition syndromes. J. Genet. Couns. 26, 387-434. DOI
62	Xue, S., Wang, Y., Han, X., Yi, H., Jiang, W., Si, S., Guo, H. and Li, Z. (2019) Novel cathepsin K inhibitors block osteoclasts in vitro and increase spinal bone density in zebrafish. RSC Adv. 9, 8600-8607. DOI
63	Zheng, Z., Geng, J., Jiang, Y., Zhang, M., Yang, R., Ge, G. and Zhang, X. (2021) Kidney diseases. In Clinical Molecular Diagnostics (S. Pan and J. Tang, Eds.), pp. 553-582. Springer, Singapore.
64	Samaee, H., Mohsenzadegan, M., Ala, S., Maroufi, S. S. and Moradimajd, P. (2020) Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. Int. Immunopharmacol. 89, 107018. DOI
65	Van Horn, L., Carson, J. A., Appel, L. J., Burke, L. E., Economos, C., Karmally, W., Lancaster, K., Lichtenstein, A. H., Johnson, R. K., Thomas, R. J., Vos, M., Wylie-Rosett, J. and Kris-Etherton, P.; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Stroke Council (2016) Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association. Circulation 134, e505-e529. DOI
66	Vijayakumar, N. and Subramanian, P. (2010b) Protective effect of Semecarpus anacardium nut extract against hyperammonemia in rats. J. Herb. Med. Toxicol. 4, 77-82.
67	Vondracek, S. F. and Linnebur, S. A. (2009) Diagnosis and management of osteoporosis in the older senior. Clin. Interv. Aging 4, 121-136. DOI
68	Yang, G., Nowsheen, S., Aziz, K. and Georgakilas, A. G. (2013) Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol. Ther. 139, 392-404. DOI
69	Sellami, M., Riahi, H., Maatallah, K., Ferjani, H., Bouaziz, M. C. and Ladeb, M. F. (2020) Skeletal fluorosis: don't miss the diagnosis! Skelet. Radiol. 49, 345-357.
70	Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., Ebeling, P. R., Einhorn, T. A., Genant, H. K., Geusens, P., Klaushofer, K., Lane, J. M., McKiernan, F., McKinney, R., Ng, A., Nieves, J., O'Keefe, R., Papapoulos, S., Howe, T. S., van der Meulen, M. C., Weinstein, R. S. and Whyte, M. P. (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 29, 1-23. DOI
71	Skjodt, M. K., Frost, M. and Abrahamsen, B. (2019) Side effects of drugs for osteoporosis and metastatic bone disease. Br. J. Clin. Pharmacol. 85, 1063-1071. DOI
72	Skowronska-Jozwiak, E. and Lorenc, R. S. (2006) Metabolic bone disease in children: etiology and treatment options. Treat. Endocrinol. 5, 297-318. DOI
73	Ethgen, O., Hiligsmann, M., Burlet, N. and Reginster, J. Y. (2016) Costeffectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures. Osteoporos. Int. 27, 301-308. DOI
74	Brini, M., Ottolini, D., Cali, T. and Carafoli, E. (2013) Calcium in health and disease. Met. Ions Life Sci. 13, 81-137. DOI
75	Cashman, K. D., Ritz, C., Adebayo, F. A., Dowling, K. G., Itkonen, S. T., Ohman, T., Skaffari, E., Saarnio, E. M., Kiely, M. and Lamberg-Allardt, C. (2019) Differences in the dietary requirement for vitamin D among Caucasian and East African women at Northern latitude. Eur. J. Nutr. 58, 2281-2291. DOI
76	Cusano, N. E., Rubin, M. R., Irani, D., Sliney, J. and Bilezikian, J. P. (2013) Use of parathyroid hormone in hypoparathyroidism. J. Endocrinol. Invest. 36, 1121-1127. DOI
77	Jiang, M., Liu, R., Liu, L., Kot, A., Liu, X., Xiao, W., Jia, J., Li, Y., Lam, K. and Yao, W. (2020) Identification of osteogenic progenitor celltargeted peptides that augment bone formation. Nat. Commun. 11, 4278-4292. DOI
78	Klemmer, V. A., Khera, N., Siegenthaler, B. M., Bhattacharya, I., Weber, F. E. and Ghayor, C. (2021) Effect of N-Vinyl-2-Pyrrolidone (NVP), a bromodomain-binding small chemical, on osteoblast and osteoclast differentiation and its potential application for bone regeneration. Int. J. Mol. Sci. 22, 11052. DOI
79	Guo, Y., Lu, N. and Bai, A. (2013) Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed. Res. Int. 2013, 581631.
80	Gennari, C. (2001) Calcium and vitamin D nutrition and bone disease of the elderly. Public Health Nutr. 4, 547-559. DOI
81	Haboubi, N. and Jones, S. (2007) Coeliac disease. From A-Z. Expert Opin. Ther. Pat. 17, 799-817. DOI
82	Herford, A. S. (2017) The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillofacial trauma. Chin. J. Traumatol. 20, 1-3. DOI
83	Hernlund, E., Svedbom, A., Ivergard, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E. V., Jonsson, B. and Kanis, J. A. (2013) Osteoporosis in the European Union: medical management, epidemiology, and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. 8, 136. DOI
84	Hossein-nezhad, A. and Holick, M. F. (2013) Vitamin D for health: a global perspective. Mayo Clin. Proc. 88, 720-755. DOI
85	Izumiyama, T., Yu, M. and Eiji, I. (2020) Tocilizumab was effective in repairing the large geode in a patient with rheumatoid arthritis. Case Rep. Rheumatol. 2020, 8899391.
86	Srivastava, S. and Flora, S. (2020) Fluoride in drinking water and skeletal fluorosis: a review of the global impact. Curr. Environ. Health Rep. 7, 140-146. DOI
87	Anagnostis, P., Gkekas, N. K., Potoupnis, M., Kenanidis, E., Tsiridis, E. and Goulis, D. G. (2019) New therapeutic targets for osteoporosis. Maturitas 120, 1-6. DOI
88	Soyka, L. A., Wesley, P. and Klibanski, F. A. (2000) Hormonal determinants and disorders of peak bone mass in children. J. Clin. Endocrinol. Metab. 85, 3951-3963. DOI
89	Sozen, T., Ozisik, L. and Basaran, N. C. (2017) An overview and management of osteoporosis. Eur. J. Rheumatol. 4, 46-56. DOI
90	Stoffer, K., Bistas, K. G., Reddy, V. and Shah, S. (2022) Abciximab. StatPearls.
91	Swanson, C. M., Shea, S. A., Stone, K. L., Cauley, J. A., Rosen, C. J., Redline, S., Karsenty, G. and Orwoll, E. S. (2015) Obstructive sleep apnea and metabolic bone disease: insights into the relationship between bone and sleep. J. Bone Miner. Res. 30, 199-211. DOI
92	Tarantino, U., Baldi, J., Celi, M., Rao, C., Liuni, F. M., Iundusi, R. and Gasbarra, E. (2013) Osteoporosis and sarcopenia: the connections. Aging Clin. Exp. Res. 25, S93-S95.
93	Kapic, E., Becic, F. and Kusturica, J. (2004) Basiliximab, mechanism of action and pharmacological properties. Med. Arh. 58, 373-376.
94	Juhlin, C. C. and Erickson, L. A. (2021) Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice. Endocr. Pathol. 32, 17-34. DOI
95	Gopinath, P. and Mihai, R. (2011) Hyperparathyroidism. Surgery 29, 451-458. DOI
96	Kanis, J. A., Cooper, C., Rizzoli, R. and Reginster, J. Y. (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 30, 3-44. DOI
97	Tu, K. N., Lie, J. D., Wan, C., Cameron, M., Austel, A. G., Nguyen, J. K., Van, K. and Hyun, D. (2018) Osteoporosis: a review of treatment options. P T 43, 92-104.
98	Akuno, M. H., Nocella, G., Milia, E. P. and Gutierrez, L. (2019) Factors influencing the relationship between fluoride in drinking water and dental fluorosis: a ten-year systematic review and meta-analysis. J. Water Health 17, 845-862. DOI
99	Tarantino, U., Cariati, I., Greggi, C., Gasbarra, E., Belluati, A., Ciolli, L., Maccauro, G., Momoli, A., Ripanti, S., Falez, F. and Brandi, M. L. (2021) Skeletal system biology and smoke damage: from basic science to medical clinic. Int. J. Mol. Sci. 22, 6629. DOI
100	Thanh, N. C., Devi Rajeswari, V., Narayanan, M., Kandasamy, S., Chinnathambi, A., Ali Alharbi, S., Van Le, Q. and Kathirvel, B. (2021) Evaluation of probiotic susceptibility of virulent Aeromonas sp. by a study on gut histology of Cyprinus carpio. Process Biochem. 111, 154-159. DOI
101	Curtis, E. M., Harvey, N. C. and Cooper, C. (2018) The burden of osteoporosis. In Osteoporosis: a Lifecourse Epidemiology Approach to Skeletal Health, pp. 1-20. CRC Press.
102	Wei, C. H. and Harari, A. (2012) Parathyroid carcinoma: update and guidelines for management. Curr. Treat. Options Oncol. 13, 11-23. DOI
103	Yoshimura, N., Muraki, S., Oka, H., Iidaka, T., Kodama, R., Kawaguchi, H., Nakamura, K., Tanaka, S. and Akune, T. (2017) Is osteoporosis a predictor for future sarcopenia or vice versa? Four-year observations between the second and third ROAD study surveys. Osteoporos. Int. 28, 189-199. DOI
104	Ciobanu, G., De Angelis, F., Slabari, E. and Pompa, G. (2021) Bone mineralization and immediate function of six dental implants in patients with Klinefelter syndrome. Clin. Case Rep. 9, e03142.
105	Cooper, C., Westlake, S., Harvey, N., Javaid, K., Dennison, E. and Hanson, M. (2006) Review: developmental origins of osteoporotic fracture. Osteoporos. Int. 17, 337-347. DOI